Simcere Pharmaceutical Group Ltd - Company Profile
Powered by 
All the sales intelligence you need on Simcere Pharmaceutical Group Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Simcere Pharmaceutical Group Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Simcere Pharmaceutical Group Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Simcere Pharmaceutical Group Ltd (Simcere) is a pharmaceutical company that discovers, develops and markets branded generic and prescription pharmaceutical products. The company's pipeline products include endostar which treats thoracoabdominal effusions; SIM0270(SERD BM) targets breast cancer; TGRX-326 for non-small cell lung cancer; SIM0237 which targets non-muscle invasive bladder cancer; SIM0500 treats multiple myeloma; SIM0395 for glioblastoma; SIM0501, SIM0508, SIM0505, SIM0686, SIM0323, SIM0609, SIM0610, SIM0613, SIM0688, SIM0532 and SIM0512 targets solid tumors; among others. It also offers prescription products for therapeutic areas including oncology, neuroscience, autoimmune, cardiovascular, anti-infection and others. The company’s brands include ENZESHU, LOWVO, Endostar, JEPASO, Enlength, Enlitai, QUVIVQ, among others. Simcere is headquartered in Nanjing, Jiangsu, China.
Headquarters
China
Address
699 - 18 Xuanwu Avenue Xuanwu Distric, Nanjing, Jiangsu, 210042
Website
www.simcere.com
No of Employees
7,038
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
2096 (HKG)
Revenue (2024)
$1.1B
16.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
86.2%
(2024 vs 2023)
Market Cap*
$3.2B
Net Profit Margin (2024)
XYZ
59.7%
(2024 vs 2023)
* As of and is in US$
Simcere Pharmaceutical Group Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Endostar |
| Endostar: Thoracoabdominal Effusions | Sanbexin |
| SIM0270: Breast Cancer | ENZESHU |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company entered into an agreement with Vigonvita Life Science Co., Ltd. to develop and commercialize deuterated remididevir hydrobromide for the treatment of respiratory syncytial virus infection and human metapneumovirus infection. |
| 2025 | Contracts/Agreements | In December, the company entered into a licensing partnership with Ipsen, granting global rights for SIM0613 outside of Greater China. |
| 2025 | Regulatory Approval | In December, Simcere Zaiming received a grant designation by the U.S. Food and Drug Administration for Envafolimab, a subcutaneous PD-L1 antibody for the treatment of gastric cancer and gastroesophageal junction cancer. |
Competitor Comparison
| Key Parameters | Simcere Pharmaceutical Group Ltd | Jiangsu Nhwa Pharmaceutical Co Ltd | Duality Biotherapeutics Inc | Shenzhen Chipscreen Biosciences Co Ltd | Qilu Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Nanjing | Xuzhou | Shanghai | Shenzhen | Jinan |
| State/Province | Jiangsu | Jiangsu | Shanghai | Guangdong | Shandong |
| No. of Employees | 7,038 | 6,003 | 231 | 1,002 | 39,000 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ren Jinsheng | Chairman | Executive Board | 2004 | 63 |
| Wan Yushan | Chief Financial Officer; Director; Joint Secretary | Executive Board | 2017 | 55 |
| Wang Xi | Director; Vice President | Executive Board | 2023 | 43 |
| Tang Renhong | Chief Executive Officer - Simcere Zaiming; Director; Chairman - Simcere Zaiming | Executive Board | 2022 | 46 |
| Zhou Yunshu | Chief Executive Officer | Senior Management | 2026 | 54 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer